Hims & Hers Health ($HIMS) Insider Trading & Smart Money Activity
Hims & Hers Health, Inc. ($HIMS) has 27 insider trades and 2 analyst ratings on file. In the last 12 months on the open market, no insider bought and 5 insiders sold ($3.25M), net -$3.25M.
- Insider buyers (12 mo)
- 0
- Insider sellers (12 mo)
- 5
- Net insider $ (12 mo)
- -$3.25M
- Congress trades (12 mo)
- 0
- 13F moves on file
- 0
- Analyst ratings on file
- 2
HIMS insider buying and selling by quarter
| Quarter | Insider buys | Insider sales | Congress buys / sales | 13F added / cut |
|---|---|---|---|---|
| Q1 2026 | 0 | 0 | 0 / 0 | 0 / 0 |
| Q2 2026 | 0 | 4 · $1.76M | 0 / 0 | 0 / 0 |
| Q3 2026 | 0 | 3 · $1.33M | 0 / 0 | 0 / 0 |
| Q4 2026 | 0 | 2 · $159.98K | 0 / 0 | 0 / 0 |
Insider buys and sales count open-market trades only (Form 4 codes P and S). Grants, option exercises and tax withholding are left out.
All HIMS insider, congress, 13F and analyst activity
| Date | Source | Who | Action | Shares | Value / amount | ΔOwn | 1W | 1M | 6M | Filing | Story |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Insider | Boughton SoleilChief Legal Officer | Sell (Open-market sale) 10b5-1 | 3.46K sh | $100.58K | Read | ||||||
| Insider | Okupe OluyemiChief Financial Officer | Sell (Open-market sale) 10b5-1 | 2K sh | $59.40K | -4.2% | — | |||||
| Insider | Boughton SoleilChief Legal Officer | Sell (Open-market sale) 10b5-1 | 3.46K sh | $100.96K | -0.8% | — | |||||
| Insider | Okupe OluyemiChief Financial Officer | Sell (Open-market sale) 10b5-1 | 29.28K sh | $876.85K | -5.7% | — | |||||
| Insider | Okupe OluyemiChief Financial Officer | Sell (Open-market sale) 10b5-1 | 12.31K sh | $354.86K | +5.0% | — | |||||
| Analyst | Canaccord Genuity | Reiterates to buy | PT $40 | -4.0% | -26.1% | Read | |||||
| Insider | Oluyemi OkupeChief Financial Officer | Sell (Option exercise) | 6.38K sh | -0.4% | -5.5% | — | |||||
| Insider | Oluyemi OkupeChief Financial Officer | Buy (Option exercise) | 6.38K sh | $31.94K | -0.4% | -5.5% | — | ||||
| Analyst | Barclays | Reiterates to buy | PT $39 | -7.8% | -7.8% | Read | |||||
| Insider | Mohamed ElshenawyCTO | Sell (Open-market sale) 10b5-1 | 30.04K sh | $946.26K | +2.5% | +3.0% | — | ||||
| Insider | Michael ChiChief Operating Officer | Sell (Open-market sale) 10b5-1 | 14.03K sh | $441.85K | +2.5% | +3.0% | — | ||||
| Insider | Irene BecklundPAO | Sell (Open-market sale) 10b5-1 | 4.49K sh | $141.44K | +2.5% | +3.0% | — | ||||
| Insider | Irene BecklundPAO | Sell (Open-market sale) 10b5-1 | 7.57K sh | $229.08K | +4.7% | +7.0% | — | ||||
| Insider | David Wells | Sell (Option exercise) | 957 sh | +11.2% | +23.2% | — | |||||
| Insider | David Wells | Buy (Option exercise) | 957 sh | +11.2% | +23.2% | — | |||||
| Insider | Christopher Payne | Sell (Option exercise) | 10.69K sh | +11.2% | +23.2% | — | |||||
| Insider | Christopher Payne | Buy (Option exercise) | 10.69K sh | +11.2% | +23.2% | — | |||||
| Insider | Anja Manuel | Sell (Option exercise) | 10.04K sh | +11.2% | +23.2% | — | |||||
| Insider | Anja Manuel | Buy (Option exercise) | 10.04K sh | +11.2% | +23.2% | — | |||||
| Insider | Mohamed ElshenawyCTO | Buy (Option exercise) | 282.60K sh | +11.2% | +23.2% | Read | |||||
| Insider | Carroll Patrick HarrisonChief Medical Officer | Sell (Option exercise) | 435 sh | +11.2% | +23.2% | — | |||||
| Insider | Carroll Patrick HarrisonChief Medical Officer | Buy (Option exercise) | 435 sh | +11.2% | +23.2% | — | |||||
| Insider | Soleil BoughtonChief Legal Officer | Sell (Option exercise) | 42.26K sh | +11.2% | +23.2% | Read | |||||
| Insider | Deborah AutorChief Policy Officer | Sell (Tax withholding) | 15.40K sh | $464.50K | +11.2% | +23.2% | Read | ||||
| Insider | David Wells | Sell (Option exercise) | 3.66K sh | +22.9% | +19.1% | Read | |||||
| Insider | David Wells | Buy (Option exercise) | 3.66K sh | +22.9% | +19.1% | Read | |||||
| Insider | Kare Schultz | Sell (Option exercise) | 3.66K sh | +22.9% | +19.1% | Read | |||||
| Insider | Delos Cosgrove | Buy (Option exercise) | 3.66K sh | +22.9% | +19.1% | Read | |||||
| Insider | Deborah AutorChief Policy Officer | Sell (Option exercise) | 3.66K sh | +22.9% | +19.1% | Read |
1W / 1M / 6M = how HIMS moved from the trade or filing date.
Insider trading in HIMS: who is buying and selling
| Insider | Role | Trades | Open-market net | Shares held | Last trade |
|---|---|---|---|---|---|
| Boughton Soleil | Chief Legal Officer | 2 | -$201.53K | Oct 14, 2026 | |
| Okupe Oluyemi | Chief Financial Officer | 3 | -$1.29M | Oct 1, 2026 | |
| Oluyemi Okupe | Chief Financial Officer | 2 | — | Jun 22, 2026 | |
| Mohamed Elshenawy | CTO | 2 | -$946.26K | Jun 17, 2026 | |
| Irene Becklund | PAO | 2 | -$370.52K | Jun 17, 2026 | |
| Michael Chi | Chief Operating Officer | 1 | -$441.85K | Jun 17, 2026 | |
| David Wells | 4 | — | Jun 15, 2026 | ||
| Christopher Payne | 2 | — | Jun 15, 2026 | ||
| Anja Manuel | 2 | — | Jun 15, 2026 | ||
| Carroll Patrick Harrison | Chief Medical Officer | 2 | — | Jun 15, 2026 | |
| Deborah Autor | Chief Policy Officer | 2 | — | Jun 15, 2026 | |
| Soleil Boughton | Chief Legal Officer | 1 | — | Jun 15, 2026 | |
| Kare Schultz | 1 | — | Jun 11, 2026 | ||
| Delos Cosgrove | 1 | — | Jun 11, 2026 |
Analyst ratings on HIMS
Frequently asked questions
Are HIMS insiders buying or selling?
Over the last 12 months 0 insiders made 0 open-market purchases worth $0 and 5 insiders made 9 open-market sales worth $3.25M, a net -$3.25M.
What is the latest insider trade in HIMS?
Boughton Soleil, Chief Legal Officer filed a sell (open-market sale) of 3.46K sh worth $100.58K on Oct 14, 2026.
Other drug manufacturers - specialty & generic stocks
Data comes from public SEC Form 4 and 13F filings and STOCK Act disclosures. Dates are the trade or filing date reported. This page is for research only and is not investment advice.
Get a text when insiders, Congress or big funds trade a stock.
Free. Reply STOP anytime.